AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7865647
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg weekend
Trial: 2577500
Drug: SK&F 94482
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK&F 94482 (BMY-25368) 400 mg
Trial: 778649
Drug: Furosemide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1.5 to 6.0 mg/kg every 4 h)
Trial: 22554102
Drug: 0.13% hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.13% hyaluronic acid (HA) solution
Trial: 15743923
Drug: Low-dose cocaine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cocaine (75 mg/70 kg) and codeine (60 mg/70 kg) administered subcutaneously and orally on alternating days for a total of three doses each during week 4.
Trial: 15743923
Drug: High-dose cocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cocaine (150 mg/70 kg) and codeine (120 mg/70 kg) administered during week 7.
Trial: 12218280
Drug: Daily supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supervised toothbrushing with toothpaste containing 1,000 ppm fluoride and 0.13% calcium glycerophosphate on school-days, combined with recommended daily home use.
Trial: 12218280
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no intervention other than 6-monthly clinical examinations.
Trial: 2672807
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg three times daily (n = 113)
Trial: 362875
Drug: Migen vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migen vaccine (6-injection course)
Trial: 362875
Drug: Migen vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migen vaccine (6-injection course + 6 maintenance injections)
Trial: 362875
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 injections)
Trial: 362875
Drug: Migen vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migen vaccine (standard course of 6 injections)
Trial: 30755410
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapies (patches and gum)
Trial: 28646590
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 mg) plus conventional therapy
Trial: 30033514
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus conventional therapy
Trial: 26113676
Drug: Everolimus (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (2.5 mg·day(-1) escalated to 10 mg·day(-1))
Trial: 21597124
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT); 2, 2-hour group sessions.
Trial: 19954709
Drug: TJ‐48 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ‐48 (7.5 g per day from 21 days before surgery to the day before surgery)
Trial: 16912578
Drug: Weekly idursulfase
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly idursulfase (0.5 mg/kg)
Trial: 16912578
Drug: Every-other-week idursulfase
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Every-other-week idursulfase (0.5 mg/kg)
Trial: 11384805
Drug: 20% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% human albumin 50 ml (n: 82)
Trial: 11384805
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (200/0.5) 500 ml (n: 85)
Trial: 11384805
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 ml 0.9% NaCl solution) (n: 83)
Trial: 9436574
Drug: Heparin-bonded oxygenator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded oxygenator (group H, n = 11)
Trial: 8299434
Drug: Adjusting food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusting food and/or insulin in response to hyperglycemia
Trial: 8299434
Drug: Adjusting insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjusting insulin dose for meal size and content
Trial: 24118850
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) with leuprorelin
Trial: 18458958
Drug: Fluoxetine (short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (short-term use)
Trial: 16385649
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate (200 mg daily for 2 weeks every 3 months)
Trial: 14674833
Drug: l,3,5(10),16-estratetraen-3-ol (EST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l,3,5(10),16-estratetraen-3-ol (EST)
Trial: 10620210
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral calcitriol, N = 20
Trial: 10620210
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous calcitriol, N = 21
Trial: 26433700
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation (BA) treatment
Trial: 8871414
Drug: Automatic Thoughts
RxNorm normalized name: AMMONIA,AROMATIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic Thoughts (AT) treatment
Trial: 1514533
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium supplementation (magnesium sulphate, 3 g before each CDDP administration)
Trial: 1514533
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (magnesium pidolate, 2 g orally every 8 hours on days 2 to 21 of each CDDP course)
Trial: 2268862
Drug: Ketoprofen 25
RxNorm normalized name: ketoprofen 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 25 mg
Trial: 29492934
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg
Trial: 29653328
Drug: Ketogenic Diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic Diet (KD) therapy
Trial: 17689147
Drug: Miglustat 200
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Miglustat 200 mg three times a day
Trial: 10021953
Drug: Propofol administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during thoracic epidural anaesthesia
Trial: 10021953
Drug: Propofol administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during lumbar epidural anaesthesia
Trial: 3171374
Drug: Benzocaine lozenges
RxNorm normalized name: Benzocaine Lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine lozenges (10 mg)
Trial: 28179035
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Trial: 25432788
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg starting dose, oral once-daily)
Trial: 24645611
Drug: Polylactic acid
RxNorm normalized name: Polylactic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polylactic acid gel (PLA-G) used under the surface of the auxiliary operative wound in the treatment group.
Trial: 24645611
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (treatment and control).
Trial: 20064022
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum perforatum ointment applied 3 times a day for 16 days
Trial: 20064022
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied 3 times a day for 16 days
Trial: 18562776
Drug: Artichoke-leaf extract,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke-leaf extract, 400 mg, 3 times a day for 5 weeks
Trial: 12015788
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ER-lovastatin
Trial: 12015788
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ER-lovastatin
Trial: 12015788
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ER-lovastatin
Trial: 1792411
Drug: Bamiphylline (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamiphylline (1.2 g daily for 7 days)
Trial: 7303692
Drug: Clopenthixol (Sordinol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopenthixol (Sordinol, Ciatyl) in small dosage
Trial: 28376818
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) with behavioral support
Trial: 15888512
Drug: High-dose acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acute tryptophan depletion (ATD)
Trial: 15888512
Drug: Low-dose acute
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acute tryptophan depletion (ATD)
Trial: 12563237
Drug: Aggressive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive fluid management (16 to 18 mL x kg(‐1) x h(‐1))
Trial: 12563237
Drug: Conservative fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative fluid management (8 mL x kg(‐1) x h(‐1))
Trial: 10448545
Drug: Sumatriptan 6
RxNorm normalized name: sumatriptan 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 6 mg s.c.
Trial: 1916034
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg at 08.00 h
Trial: 1916034
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg at 22.00 h
Trial: 6226480
Drug: Oral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenge with a mixture of 2.5 mg nickel, 2.5 mg chromium, and 1 mg cobalt salts
Trial: 6226480
Drug: Diet planned
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diet planned to reduce daily intake of respective metals
Trial: 26372082
Drug: Half-sized food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-sized food portions with modest nonfood incentives (e.g., inexpensive headphones for children, gift cards or frequent flyer miles for adults, small amounts of money for restaurant customers)
Trial: 22954666
Drug: Exemestane (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25mg daily) alone
Trial: 22954666
Drug: Tamoxifen (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20mg daily) followed by exemestane
Trial: 22954666
Drug: Exemestane (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25mg daily)
Trial: 19846851
Drug: Cisplatin alone
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin alone (80 mg/m² every 14 days)
Trial: 19846851
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus doxorubicin (administered in three preoperative cycles and two postoperative cycles)
Trial: 8942462
Drug: Fluoxetine augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine augmentation
Trial: 1887483
Drug: Albendazole 15
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 15 mg/kg/d for 30 d
Trial: 1887483
Drug: Praziquantel 50
RxNorm normalized name: praziquantel 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 50 mg/kg/d for 15 d
Trial: 6138064
Drug: Midazolam 20
RxNorm normalized name: midazolam 200 mg/200 mL-D5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 20 mg
Trial: 31698695
Drug: Flavonoid-rich mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-rich mixed berry smoothie (400 mL) containing equal amounts of blueberry, strawberry, raspberry, and blackberry, n = 20
Trial: 30394200
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of TB knowledge (lack of knowledge about TB transmission, cause of TB, unawareness of consequences of stopping treatment)
Trial: 30394200
Drug: Treatment experience
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment experience (lack of TB education provided by TB nurse, use of loose vs. fixed-dose combinations)
Trial: 24534073
Drug: Total bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total bilirubin levels >8 and ≤10 μmol/L
Trial: 24534073
Drug: Total bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total bilirubin levels >10 and ≤13 μmol/L
Trial: 24534073
Drug: Total bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total bilirubin levels >13 μmol/L
Trial: 24534073
Drug: Total bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total bilirubin levels ≤8 μmol/L
Trial: 22878452
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of sodium hyaluronate and diquafosol tetrasodium
Trial: 22878452
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate monotherapy
Trial: 17379049
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of cinnarizine 20 mg + dimenhydrinate 40 mg
Trial: 7921339
Drug: Cinnarizine 50
RxNorm normalized name: cinnarizine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 50 mg
Trial: 17379049
Drug: Dimenhydrinate 100
RxNorm normalized name: dimenhydrinate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate 100 mg
Trial: 12019378
Drug: Insulin-enhanced cardioplegia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-enhanced cardioplegia (10 IU/L insulin)
Trial: 10219332
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of filgrastim (5 micrograms/kg) starting +1 day postchemotherapy
Trial: 10219332
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of filgrastim (5 micrograms/kg) starting +5 days postchemotherapy
Trial: 10219332
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of filgrastim
Trial: 10219332
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of filgrastim
Trial: 29634604
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection
Trial: 2163450
Drug: Enalapril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 10 mg once daily
Trial: 2163450
Drug: Lisinopril, 10
RxNorm normalized name: Lisinopril, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril, 10 mg once daily
Trial: 661731
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg highly purified dextrothyroxine for 12 weeks
Trial: 661731
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg beta‐pyridylcarbinol for 12 weeks
Trial: 661731
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 4 mg dextrothyroxine and 600 mg beta‐pyridylcarbinol daily for 8 weeks
Trial: 661731
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with dextrothyroxine
Trial: 661731
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with beta‐pyridylcarbinol
Trial: 661731
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of dextrothyroxine and beta‐pyridylcarbinol
Trial: 29402870
Drug: Mentalization-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-Based Treatment (MBT) in combination with SUD treatment, n = 24
Trial: 29402870
Drug: SUD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUD treatment alone, n = 22
Trial: 27393009
Drug: Sprifermin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (100 μg)
Trial: 15892532
Drug: Sealants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants with a bonding agent
Trial: 15892532
Drug: Sealants without
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants without a bonding agent
Trial: 12510039
Drug: Two infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two infusions of 6 mg of natalizumab per kilogram
Trial: 12510039
Drug: Two infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two infusions of 3 mg of natalizumab per kilogram
Trial: 12510039
Drug: Groups receiving
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups receiving two infusions of natalizumab
Trial: 8834062
Drug: Low-intensity anticoagulation
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity anticoagulation (e.g., warfarin)
Trial: 1829981
Drug: Metoprolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (1 x 100 mg/day)
Trial: 1829981
Drug: Cilazapril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (1 x 2.5 mg/day)
Trial: 6410908
Drug: methylprednisolone 80
RxNorm normalized name: methylPREDNISolone 80 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone 80 mg intravenously plus Vivonex‐HN, 2 L/day po
Trial: 6410908
Drug: methylprednisolone 80
RxNorm normalized name: methylPREDNISolone 80 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone 80 mg intravenously plus total parenteral nutrition, 2.5 L/day
Trial: 6410908
Drug: total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total parenteral nutrition, 2.5 L/day
Trial: 6410908
Drug: Vivonex‐HN, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vivonex‐HN, 2 L/day po
Trial: 30910388
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control (maintenance of sinus rhythm by catheter ablation and/or antiarrhythmic drugs)
Trial: 29527702
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil once a day for 6 weeks
Trial: 29527702
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral multivitamin tablet) once a day for 6 weeks
Trial: 27630326
Drug: 2 vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 vs. 5 years of treatment with zoledronic acid
Trial: 20054553
Drug: Epirubicin 20
RxNorm normalized name: epiRUBicin 200 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 20 mg/40 ml saline
Trial: 20054553
Drug: Epirubicin 50
RxNorm normalized name: epiRUBicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 50 mg/100 ml
Trial: 16708818
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Jianweiyuyang granules and ranitidine capsules